Allegro MicroSystems enters the week with a sharp internal tension: the stock has surged 14% in five days and 24% in a month, yet short sellers have been adding positions into that rally, not retreating from it.
Short interest is the standout story here. It climbed roughly 13.5% over the past week to 6.5% of the free float — a meaningful jump that arrived as the stock broke to multi-month highs above $53. The move is notable because short sellers typically cover into rising prices, not lean in. Instead, roughly 1.4 million additional shares were added to the borrow book between early and mid-June. That said, the borrow market itself is far from stressed. Availability is running at 405% — meaning roughly four shares are still sitting available in the lending pool for every one already borrowed — and cost to borrow has held steady at around 0.52%, barely moved from where it was a month ago. There is no squeeze pressure here. The ORTEX short score of 57.8 is elevated but has been roughly flat all week, suggesting the build is gradual rather than a panic-driven piling-on. Options traders are similarly unexcited: the put/call ratio is 0.29, slightly below its 20-day average, with a z-score near zero. Neither camp is taking a strong directional stance through the options market.
What the Street does agree on is the direction of travel. Analyst consensus is buy, with a mean price target of $54.36 — remarkably close to where the stock is trading at $53.29, which explains why targets are becoming relevant again. Following the May 7 earnings print, five firms raised their targets, with UBS lifting to $55, Wells Fargo jumping from $48 to $56, and Mizuho moving from $44 to $54. All maintained positive ratings. The bull case rests on a fifth consecutive quarter-over-quarter booking increase of 20%, with management pointing to normalising inventories, a growing backlog, and early signs of component shortages that typically precede an up-cycle. The bear case is less about demand and more about margins: gross margin pressure from pricing declines that are outpacing supplier cost reductions has forced downward revisions to profitability estimates. EPS momentum over 90 days ranks in the 96th percentile, and 12-month forward EPS growth is exceptional — but the valuation has re-rated accordingly. The P/E multiple has expanded roughly 8 points in a month, and at 43x trailing earnings with EV/EBITDA around 31x, the stock is pricing in a meaningful recovery rather than just a stabilisation.
Insider activity adds a mild note of caution. Every transaction in the past 90 days has been a sale. The CFO sold nearly $1.6 million worth of shares on May 15 at $43.10. The General Counsel, the Chief Accounting Officer, and two Senior Vice Presidents all sold on the same day, with a further SVP sale at $52.72 in early June. None are at levels that constitute a distress signal — many look like scheduled plan sales — but the aggregate net value of sales over 90 days runs close to $9.7 million, and there have been no offsetting purchases. For a stock now trading 24% above where most of those sales were executed, the insider signal is at minimum unremarkable.
The earnings history is worth flagging ahead of the next print, due July 30. The May 7 release produced a 4.7% one-day decline and a 12.5% five-day drop — a clear pattern of sell-the-news even when the numbers were constructive enough to trigger multiple analyst upgrades. With short interest still building, the stock trading just above the mean analyst target, and the CFO having sold shares six weeks ago at a 19% discount to today's price, the July 30 print is the natural next focal point: the question will be whether the booking cycle momentum is translating into margin recovery fast enough to justify a valuation that has moved well ahead of the Street's consensus target.
See the live data behind this article on ORTEX.
Open ALGM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
